Volume | 83,182 |
|
|||||
News | - | ||||||
Day High | 10.42 | Low High |
|||||
Day Low | 10.13 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
KalVista Pharmaceuticals Inc | KALV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.23 | 10.13 | 10.42 | 10.35 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,693 | 83,182 | $ 10.28 | $ 854,857 | - | 7.21 - 16.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:58:58 | 1 | $ 10.3696 | USD |
KalVista Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
438.76M | 42.19M | - | 0 | -92.91M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
KalVista Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KALV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.53 | 11.78 | 10.13 | 11.15 | 343,937 | -1.15 | -9.97% |
1 Month | 11.08 | 12.4555 | 10.13 | 11.50 | 529,313 | -0.70 | -6.32% |
3 Months | 15.81 | 16.88 | 10.13 | 13.48 | 831,255 | -5.43 | -34.35% |
6 Months | 8.48 | 16.88 | 7.21 | 12.62 | 580,903 | 1.90 | 22.41% |
1 Year | 7.97 | 16.88 | 7.21 | 11.81 | 405,353 | 2.41 | 30.24% |
3 Years | 24.61 | 30.70 | 4.12 | 12.04 | 314,485 | -14.23 | -57.82% |
5 Years | 24.03 | 45.00 | 4.12 | 16.54 | 288,790 | -13.65 | -56.80% |
KalVista Pharmaceuticals Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. |